CorMedix raised its Q2 sales forecast to $35-40M, citing wider-than-expected adoption of DefenCath by a key dialysis partner. Needham upped its price target to $20, calling the rollout a significant upside surprise. Retail sentiment turned extremely bullish as message volume jumped over 13,000%.